U.S. RESEARCH ROUNDUP-Akamai Technologies, Metacrine, Vaxcyte

Kiniksa Pharmaceuticals International

29/12/2021 07:11

Dec 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Akamai Technologies, Metacrine and Vaxcyte, on
Wednesday. 
    
  HIGHLIGHTS        
     * Akamai Technologies Inc  AKAM.O : D.A. Davidson initiates coverage with buy rating; PT $143
     * Metacrine, Inc.  MTCR.O : Jefferies assumes coverage with hold rating and PT of $1 vs $2
     * Vaxcyte Inc  PCVX.O : Jefferies assumes coverage with buy rating; target price $50
     * VBI Vaccines Inc  VBIV.O : Jefferies assumes coverage with buy rating; target of $6 vs $7
                
Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday.
Stock entries are in alphabetical order.         
     * Akamai Technologies Inc  AKAM.O : D.A. Davidson initiates coverage with buy rating; PT $143
     * Alliance Data Systems Corp  ADS.N : Jefferies cuts target price to $75 from $95
     * Altimmune Inc  ALT.O : Jefferies assumes coverage with buy rating and $30 target price
     * Arbutus Biopharma Corp  ABUS.O : Jefferies assumes coverage with hold rating and $4 PT
     * Icosavax Inc  ICVX.O : Jefferies assumes coverage with buy rating; target price $50
     * Inovio Pharmaceuticals  INO.O : Jefferies assumes coverage with hold rating; PT of $6 vs $8
     * Kiniksa Pharmaceuticals Ltd  KNSA.O : Evercore ISI cuts target price to $20 from $25
     * Metacrine, Inc.  MTCR.O : Jefferies assumes coverage with hold rating and PT of $1 vs $2
     * Vaxart Inc  VXRT.O : Jefferies assumes coverage with buy rating; target price of $12 vs $13
     * Vaxcyte Inc  PCVX.O : Jefferies assumes coverage with buy rating; target price $50
     * VBI Vaccines Inc  VBIV.O : Jefferies assumes coverage with buy rating; target of $6 vs $7
 
 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))